【摘要】 目的:探讨干扰素α-1b联合病毒唑治疗丙型病毒性肝炎的临床疗效和安全性。方法:67例丙型病毒性肝炎患者被随机分为联合治疗组(干扰素α-1b加病毒唑,32例)与对照组(单用干扰素α-1b,35例)。分别观察两组治疗前后临床症状体征的改善情况、生化应答率、病毒应答率和毒副作用。结果:治疗结束时联合治疗组临床症状体征的缓解率为96.88%,生化应答率为96.88%,病毒应答率为68.75%;对照组上述指标分别为80%、80%、48.57%.经检验无显著性差异(P>0.05)。但随访1年联合治疗组的持续应答率为43.75%,而对照组的持续应答率为14.29%,差异显著(P<0.01)。联合治疗组副作用除贫血较对照组明显外,其他与对照组相仿。结论:干扰素α-1b和病毒唑联合治疗可以增强远期抗病毒疗效且耐受性好,可成为治疗丙型肝炎的主要疗法之一。更多还原

【Abstract】 Aim:To determine the curative effect and security of combined interferon a-lb with ribavirin in treatment of hepatitis C. Methods i 67 patients with hepatitis C were randomly divided into combined curative group (interferon a-Ib and ribavirin) and contrast group (only interferon a-lb). There were 32 cases and 35 cases respectively. To observe the improvement rate of clinical sydrome, the answer rate of liver function, the answer rate of virus and the side effects. Results: In the end of therapy period, the improvement rate of clinical sydrome in combined curative group was 96. 88% . answer rate of liver function was 96- 88% .answer rate of virus was 68- 75%. The aforementioned quota in contrast group was 80%, 80%, 48. 75% correspondingly (P>0. 05). But after 1 year, the continued answer rate in combined curative group was 43. 75% .while the rate in contrast group was 14. 29%(P<0. 01). The side effects in combined curative group were similar with that in contrast group, except anemia. Conclusion; Combined treatment with interferon a-lb and ribavirin was safe and could improve the forward curative effect. This curative plan could be one of the main methods in treatment of hepatitis C.更多还原